3 1/2% Tr 25 (TY25) News

Form 8-K - Current report

Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Company aligned with FDA on key CMC topics Tonix also has completed the second and final pre-New Drug...

Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)

Gap in non-oral prescriptions relative to AHS guidelines represents an opportunity to increase awareness of...

Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024

Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering

CHATHAM, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix”...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

CHATHAM, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix”...

Tonix Pharmaceuticals Announces Proposed Public Offering

CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix”...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 8-K - Current report

Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split

CHATHAM, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or...

Form 8-K - Current report